User login
Primary tabs
Press Releases
Newport Laboratories is now part of Boehringer Ingelheim
DULUTH, Ga. — [June 12, 2018]
Boehringer Ingelheim (BI) is excited to announce that Newport Laboratories, Inc. in Worthington, Minnesota, is officially part of Boehringer Ingelheim’s animal health business unit.
Newport Laboratories enhances the service and product offerings for BI customers. By providing cutting-edge diagnostics like whole genome sequencing, metagenomics, and bioinformatics, Newport Laboratories crafts custom, autogenous vaccines that target the specific viruses or bacteria causing disease in individual livestock operations.
Scrambled eggs with a side of molecular biology
(May 5, 2017) – Dr. Priya Anbalagan added molecular biology to the menu during the Academy of Veterinary Consultants 2017 Spring Conference in Irving, Texas, March 30 through April 1. Anbalagan, senior scientist and manager of Diagnostic Services and Technology Development, Newport Laboratories, Inc., presented her research on state-of-the-art diagnostics and bovine respiratory disease to more than 130 veterinarians at a breakfast sponsored by Merial.
Anbalagan demonstrated how Newport is using cutting edge molecular technology to evaluate genetic variations of pathogens.
Randy Shirbroun talks pathology and prevention of diseases
WORTHINGTON, Minn. – Veterinarian Randy Shirbroun of Newport Laboratories Inc. addressed more than 200 bison producers regarding the pathology and prevention of diseases caused by Mycoplasma bovis. The producers had gathered for the 2016 National Bison Association Summer Conference held in June at Elk River, Minnesota. Shirbroun specializes in ruminant health issues including those seen in the American bison, which became the official U.S. national mammal in May.
Newport Laboratories releases new Mycoplasma bovis Test
Newport Laboratories, Inc. has developed a new multilocus sequence typing (MLST) technique for Mycoplasma bovis, a significant cause of disease in cattle. The new technology represents a major advancement over the previous diagnostic process and will provide increased resolution and a better assessment of genetic variation that may be associated with antigenic, or strain differences. This technological advancement utilizing molecular biology is yet another development to come from Newport Laboratories, Inc., a leader in cutting edge diagnostic technology and the manufacturer of autogenous, or custom-made vaccines. The new MLST technique evaluates 10 variable genes associated with specific Mycoplasma bovis virulence factors, including several of the variable surface proteins (VSPs).
A New Era of